Subject: Fwd: CLIP | USA Today: Hillary Clinton's 21 words clobber biotechs
From: "Ann O'Leary" <[email-masked]>
To: Joel Benenson <[email-masked]>, Mandy Grunwald <[email-masked]>, Robby Mook <[email-masked]>, Jake Sullivan <[email-masked]>, John Podesta <[email-masked]>
Date: Mon, 21 Sep 2015 09:56:35 -0700

FYI - We have started the war with Pharma!!

---------- Forwarded message ----------
From: Josh Schwerin <[email-masked]>
Date: Mon, Sep 21, 2015 at 9:45 AM
Subject: CLIP | USA Today: Hillary Clinton's 21 words clobber biotechs
To: Clips <[email-masked]>

Hillary Clinton's 21 words clobber biotechs
 Matt Krantz <http://www.usatoday.com/staff/1035/matt-krantz/>, USA TODAY 12:31
p.m. EDT September 21, 2015

http://www.usatoday.com/story/money/markets/2015/09/21/hillary-clinton-tweet-biotech/72563788/

Just a 21-word Tweet from Presidential hopeful Hillary Clinton is enough to
hammer biotech stocks.

The NYSE ARCA Biotech Index, a collection of some of the largest biotech
stocks, is down Monday 2% to $81.82. One of the most valuable biotech
stocks in the Standard & Poor's 500, Biotech (BIIB) is down 4.3% to
$301.03. And trouble in biotechs - one of the hottest corners of Wall
Street - is bleeding over to the rest of the market. The Nasdaq Composite
Index, which contains many biotech stocks, is down 0.1%.

What did Clinton say that has investors so worried? "Price gouging like
this in the specialty drug market is outrageous. Tomorrow I'll lay out oa
plan to take it on," Clinton wrote on Twitter
<https://twitter.com/HillaryClinton>. Her comments are in response to a
weekend story on from the New York Times talking about the 5,456% increase
of a 62-year-old drug called Daraprim, after its parent company, Turing
Pharmaceuticals, was bought by a former hedge-fund manager. The article
points out that these rapid price hikes are common with many "specialty
drugs."

Promises of price controls put the fear into investors - who dread
government moves to regulate the industry. And that's why just a few words
from a presidential candidate can spell trouble.

HARDEST HIT BIOTECH STOCKS IN S&P 500 MONDAY

Company, Symbol, % Ch. Monday

Biogen, BIIB, -4.3%

Vertex, VRTX, -3.2%

Alexion Pharmceuticals, ALXN, -2.9%

Baxalta, BXLT, -2.2%

Regeneron Pharmaceuticals, REGN, -2.1%

Celgene, CELG, -1.9%

Gilead Sciences, GILD, -1.1%

Amgen, AMGN, -1%

Source: S&P Capital IQ, USA TODAY

Follow Matt Krantz @mattkrantz

-- 
Josh Schwerin
Spokesperson
Hillary for America
@JoshSchwerin

-- 
Ann O'Leary
Senior Policy Advisor
Hillary for America
Cell: 510-717-5518